About
About Shionogi
Our leadership team
History and values
Global affiliates and locations
Investor relations
Sustainability
Sustainability
Tax strategy
Transparency
Governance, policies and position statements
Innovation
Innovation
Our areas of focus
Strategic partnering in Europe
Global innovation
Grants and donations
News
Investors
Careers
Contact
Europe
Worldwide
Home
News
2020
10
e-201014
Release
Medical News
2020/10/19
Shionogi announces publication of two studies in the Lancet infectious diseases highlighting the efficacy and safety of cefiderocol for the treatment of infections due to aerobic gram-negative bacteria in adults with limited treatment options